Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 88

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 88
---
 and 2023

Unless the context otherwise requires, references
to the “Company,” “Mosaic,” “we,” “our,” or “us” in this Annual Report on
Form 10-K (“Report”) refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries.

1.        Organization
and Business

Organization

Mosaic ImmunoEngineering, Inc. (the “Company,”
“Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March
24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the
treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms
to expand our pipeline based on a deep understanding of immunotherapies.

The Company has two inactive wholly owned subsidiaries:
Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions
Group, Inc.

Going Concern and Management’s Plans

The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern. At December 31, 2024, the Company had cash and cash equivalents
of $115,019 and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability
to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions, that our cash and cash equivalents
on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Annual Report on
Form 10-K.

There are a number of uncertainties associated with
our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the
continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators
that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision
to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any
additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital
will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then
existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going